20
Participants
Start Date
September 30, 2025
Primary Completion Date
June 1, 2026
Study Completion Date
June 1, 2027
Arm I Carboplatin, Paclitaxel, Pembrolizumab
Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
Arm II Carboplatin, Paclitaxel, Cetuximab
Carboplatin, AUC 5, day 1 of each cycle, each cycle every 21 days for 4 cycles Paclitaxel, 175 mg/m2, day 1 of each cycle, each cycle every 21 days for 4 cycles Cetuximab 400 mg/m2, day 1 of the first cycle and then 250 mg/m2 days 1, 8, 15 every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
Arm III Pembrolizumab
Pembrolizumab, 200 mg, day 1 of each cycle, each cycle every 21 days for 4 cycles Radiation Therapy 30Gy 1 week
Rhode Island and The Miriam Hospitals, Providence
Lead Sponsor
The Miriam Hospital
OTHER
Rhode Island Hospital
OTHER
Brown University
OTHER